These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187 [TBL] [Abstract][Full Text] [Related]
25. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil. da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488 [TBL] [Abstract][Full Text] [Related]
26. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Grisouard J; Shimizu T; Duek A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC Blood; 2015 Mar; 125(13):2131-40. PubMed ID: 25595737 [TBL] [Abstract][Full Text] [Related]
27. [The impact of autophagy on proliferation of HEL cells and hematopoietic cells of polycythemia vera patients with JAK2 V617F mutation]. Dong L; Shen X; Wei W; Shi W; Zhang G; Cao W; Li D Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):520-5. PubMed ID: 26134021 [TBL] [Abstract][Full Text] [Related]
28. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Li J; Spensberger D; Ahn JS; Anand S; Beer PA; Ghevaert C; Chen E; Forrai A; Scott LM; Ferreira R; Campbell PJ; Watson SP; Liu P; Erber WN; Huntly BJ; Ottersbach K; Green AR Blood; 2010 Sep; 116(9):1528-38. PubMed ID: 20489053 [TBL] [Abstract][Full Text] [Related]
29. JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden. Catarsi P; Rosti V; Morreale G; Poletto V; Villani L; Bertorelli R; Pedrazzini M; Zorzetto M; Barosi G; PLoS One; 2015; 10(1):e0116636. PubMed ID: 25617626 [TBL] [Abstract][Full Text] [Related]
30. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972 [TBL] [Abstract][Full Text] [Related]
31. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation. Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778 [TBL] [Abstract][Full Text] [Related]
32. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526 [TBL] [Abstract][Full Text] [Related]
34. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. Lundberg P; Takizawa H; Kubovcakova L; Guo G; Hao-Shen H; Dirnhofer S; Orkin SH; Manz MG; Skoda RC J Exp Med; 2014 Oct; 211(11):2213-30. PubMed ID: 25288396 [TBL] [Abstract][Full Text] [Related]
35. X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations. Allen C; Lambert JR; Linch DC; Gale RE Blood; 2014 Sep; 124(13):2091-3. PubMed ID: 25139350 [TBL] [Abstract][Full Text] [Related]